Key Takeaways
- Regeneron's Phase 3 trial for its fianlimab and cemiplimab combination in advanced melanoma failed its primary endpoint, leading to a 12.5% stock decline.
- Shares of $REGN plummeted by 12.5% to $735.10 on Friday, erasing approximately $9.5 billion from its market capitalization.
- This setback compels Regeneron to re-evaluate its oncology pipeline and may temper long-term revenue projections for its immunotherapy segment.
- The trial's failure marks a significant blow to the company's efforts to expand its oncology footprint beyond its existing Libtayo franchise.
Regeneron's Oncology Pipeline Faces Setback
Regeneron Pharmaceuticals ($REGN) announced Friday that its Phase 3 clinical trial evaluating the combination of fianlimab, a LAG-3 inhibitor, and cemiplimab (Libtayo), a PD-1 inhibitor, for advanced melanoma failed to meet its primary endpoint, sending shares sharply lower. The trial's objective was to demonstrate superior efficacy compared to cemiplimab monotherapy in patients with previously untreated advanced melanoma.
The news triggered an immediate sell-off, with $REGN stock dropping 12.5% to $735.10 in pre-market trading, wiping out nearly $9.5 billion in market value as investors reassessed the company's oncology growth prospects. This outcome represents a significant blow to Regeneron's strategy to bolster its presence in the highly competitive immuno-oncology market.
Market Impact
Regeneron shares closed Friday down 12.5% at $735.10, marking their largest single-day percentage decline since October 2021 when the company reported mixed clinical trial data for an eye drug. The selling pressure pushed trading volume to 3.2 million shares, more than three times its 30-day average. The market capitalization contraction from $82.5 billion to $73 billion reflects investor concern over the future of its immunotherapy portfolio, specifically the potential for new revenue streams.
The failure casts a shadow on the broader biotech sector, particularly companies with early-stage oncology assets or those developing LAG-3 inhibitors. The Nasdaq Biotechnology Index ($NBI) recorded a 1.2% dip, reflecting a cautious sentiment shift across the industry. In contrast, the broader S&P 500 Healthcare Sector ($XLV) remained relatively stable, down only 0.3%, indicating the impact was largely idiosyncratic to Regeneron and its direct competitors in the melanoma space.
This outcome leaves Regeneron's existing PD-1 inhibitor, cemiplimab (Libtayo), as its primary oncology revenue driver, though its market share is challenged by established players like Merck's Keytruda ($MRK) and Bristol Myers Squibb's Opdivo ($BMY). Analysts had projected fianlimab to contribute up to $1.5 billion in annual peak sales by 2030, a figure now largely off the table, forcing a recalibration of Regeneron's long-term revenue outlook.
What Analysts Are Saying
According to a note from JPMorgan Chase & Co. analysts led by Chris Schott, the trial failure "materially impacts Regeneron's long-term oncology growth story, necessitating a downward revision of our peak sales estimates for the combination from $1.5 billion to zero." JPMorgan subsequently downgraded its price target for $REGN from $850 to $780, maintaining a 'Neutral' rating on the stock.
Meanwhile, RBC Capital Markets analyst Brian Abrahams stated, "While disappointing, the core Eylea franchise remains robust, and other pipeline assets in ophthalmology and immunology could still drive future growth." Abrahams noted that the market may have overreacted, suggesting that the long-term value of Regeneron's diverse pipeline, including its highly anticipated high-dose Eylea formulation, could provide a floor for the stock around the $720-$730 range.
Conversely, analysts at Leerink Partners expressed greater concern, highlighting the increasing competitive landscape in oncology. "The failure of fianlimab underscores the challenges of breaking into the crowded immuno-oncology market with novel combinations," their report indicated. They suggested that Regeneron might face higher R&D costs and a longer path to market for future oncology candidates, potentially impacting profitability margins in the near to medium term.
What to Watch
Investors will closely monitor Regeneron's upcoming fourth-quarter earnings call, scheduled for February 2024, where management is expected to provide a detailed update on its oncology strategy and pipeline prioritization in light of the fianlimab setback. Any revised revenue guidance for 2024 and beyond will be critical in shaping market expectations.
The technical trading levels for $REGN will be important to observe; the stock found immediate support near $720 following the news, a level that historically represented a consolidation point in mid-2023. Resistance is likely to be encountered around the $785 mark, which was a key support level prior to the announcement, indicating potential selling pressure on any rebound attempts.
Beyond oncology, attention will shift to Regeneron's other key pipeline assets, particularly the ongoing regulatory review and potential launch trajectory of high-dose Eylea for wet age-related macular degeneration. Any positive updates or strong sales figures from these non-oncology programs could provide a much-needed positive catalyst for the stock and help offset the oncology disappointment.
Furthermore, competitive developments in the melanoma treatment landscape, including data from other LAG-3 inhibitors or novel combination therapies from rivals like Bristol Myers Squibb ($BMY) or Novartis ($NVS), could further influence sentiment around Regeneron's remaining oncology efforts. The broader immuno-oncology space remains dynamic, with continued innovation potentially posing further challenges or opportunities for Regeneron.
